InvestorsHub Logo
Post# of 252255
Next 10
Followers 59
Posts 6629
Boards Moderated 1
Alias Born 10/18/2003

Re: iwfal post# 64097

Thursday, 07/31/2008 10:26:22 AM

Thursday, July 31, 2008 10:26:22 AM

Post# of 252255
AGIX +45% AGI-1067 meets endpoint for diabetes

http://biz.yahoo.com/iw/080731/0420780.html

On July 31, 2008, AtheroGenics, Inc. issued a press release to report the company's top-line results for the ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type-2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.

The following exhibit is furnished as part of this current report on Form 8-K.

Exhibit No. Description
99.1 - Press Release dated July 31, 2008




Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.